Cand.scient. Aslaug Aamodt Muggerud from Anne-Lise Børresen-Dale's group at the Department of Genetics at the Institute for Cancer Research gave her trial lecture on the subject "Clinical utility of genetic and epigenetic markers in the management of cancer. Current status" on Friday November 13th at 10.30.
She defends her PhD thesis - entitled "Genetic and epigenetic alterations in breast tumour progression: The transition from in situ to invasive cancer" on Friday November 13th at 13.15.
Venue for both events: Auditorium U1, The Norwegian Radium Hospital at Montebello.
From major journals, first or last author from the Institute for Cancer Research
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
Ann Oncol (in press)
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells
Haematologica, 104 (5), e229
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236